Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SI-B036 in Advanced/Metastatic Solid Tumors
NCT07857616Phase 1Recruiting
- Sponsor
- SystImmune Inc.
- Start
- Jul 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SI-B036 in solid tumor, non-small cell lung cancer (NSCLC), melanoma and 1 more, sponsored by SystImmune Inc. Primary endpoints: Dose-Limiting Toxicities at 24 months, Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs), and Treatment-Emergent Adverse Events (TEAEs) at 24 months and 4 more. Started Jul 2026; status: recruiting.
02
Drugs
SI-B036
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)melanomaovarian cancer
Beyond the preview
Go deeper on NCT07857616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07857616.